Effectiveness of influenza vaccination in reducing influenza-like illness and related antibiotic prescriptions in adults from a primary care-based case-control study

He, Wenqiang; Gianacas, Christopher; Muscatello, DJ; Newall, Anthony T.; McIntyre, Peter; Cheng, Allen; Liu, Bette

doi:10.1016/j.jinf.2022.10.028

Cited by 5 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VE against HPV infection was calculated as (1-adjusted PR) × 100% as previously [ 27 , 28 ]. We estimated VE against vaccine-type HPV infection overall, by age at diagnosis (18–22, 23–27 and 28–35 years), time since vaccination (≤4, between >4 and ≤10 years compared with unvaccinated), sexual debut (vaccinated after sexual debut, vaccinated before sexual debut compared with unvaccinated) and lifetime sexual partners (≤2, ≥3).…”

Section: Methodsmentioning

confidence: 99%

Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection

Hall

et al. 2023

Epidemiol. Infect.

Self Cite

View full text Add to dashboard Cite

This study aimed to assess human papillomavirus (HPV) vaccine effectiveness (VE) against both vaccine-type and nonvaccine-type high-risk HPV (hrHPV) infection, and duration of protection in United States. The study population was female participants aged 18–35 years with an HPV vaccination history and genital testing for HPV from the National Health and Nutrition Examination Survey, 2007–2016. Participants vaccinated before sexual debut were assessed against 13 nonvaccine-type hrHPV infection including 31/33/35/39/45/51/52/56/58/59/68/73/82. Multivariable logistic regression was used to estimate VE overall, by age at diagnosis, time since vaccination and lifetime sexual partners. A total of 3866 women were included in the analysis, with 23.3% (95% CI 21.3%–25.4%) having been vaccinated (≥1 dose). VE against vaccine-type HPV18/16/11/6 infection was 58% overall, which was mainly driven by those aged 18–22 years (VE = 64%) and 23–27 years (65%). Among participants aged 18–22 years vaccinated before sexual debut, the VE was 47% (23%–64%) against 13 nonvaccine-type hrHPV and 61% (95% CI 36%–77%) against 5 selected nonvaccine-type hrHPV35/39/52/58/59. Both direct effectiveness and cross-protection maintained effective for 5–10 years post vaccination. We also found the prevalence of ever diagnosed cervical cancer among vaccinated was significantly lower (0.46%, 4/874) than that among unvaccinated participants (1.27%, 38/2992). These findings highlight the potential of significant reduction of cervical cancer following the universal HPV vaccination programme.

show abstract

Section: Methodsmentioning

confidence: 99%

Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection

Hall

et al. 2023

Epidemiol. Infect.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thorough investigation into co-infections is crucial as they can lead to severe clinical manifestations across all age groups, but particularly in elderly individuals, infants, young children, and the immunocompromised ( 11 , 28 ). Although influenza vaccination has proven to decrease hospitalization rates for pneumonia patients ( 29 ), and immunization against Spn has greatly reduced the incidence of invasive pneumococcal disease ( 30 , 31 ), the vaccines for Spn and IAV offer protection against single infections however ( 32 , 33 ), they have shown limited protection against co-infection in mice ( 34 – 36 ). Present treatments for these co-infections consist of antibiotic therapy aimed at Spn and antiviral medications targeting viruses.…”

Section: Introductionmentioning

confidence: 99%

Human monoclonal antibodies protect against viral-mediated pneumococcal superinfection

Gingerich,

Mahoney,

McCormick

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionCommunity-acquired pneumonia (CAP) is a global health concern, with 25% of cases attributed to Streptococcus pneumoniae (Spn). Viral infections like influenza A virus (IAV), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV) increase the risk of Spn, leading to severe complications due to compromised host immunity.MethodsWe evaluated the efficacy of an anti-PhtD monoclonal antibody (mAb) cocktail therapy (PhtD3 + 7) in improving survival rates in three viral/bacterial coinfection models: IAV/Spn, hMPV/Spn, and RSV/Spn.ResultsThe PhtD3 + 7 mAb cocktail outperformed antiviral mAbs, resulting in prolonged survival. In the IAV/Spn model, it reduced bacterial titers in blood and lungs by 2-4 logs. In the hMPV/Spn model, PhtD3 + 7 provided greater protection than the hMPV-neutralizing mAb MPV467, significantly reducing bacterial titers. In the RSV/Spn model, PhtD3 + 7 offered slightly better protection than the antiviral mAb D25, uniquely decreasing bacterial titers in blood and lungs.DiscussionGiven the threat of antibiotic resistance, our findings highlight the potential of anti-PhtD mAb therapy as an effective option for treating viral and secondary pneumococcal coinfections.

show abstract

Association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015–16 to 2020–21 seasons: from the VENUS study

Tsuzuki,

Murata,

Maeda

et al. 2023

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Background Seasonal influenza vaccination might be considered an antimicrobial resistance (AMR) countermeasure because it can reduce unnecessary antimicrobial use for acute respiratory infection by mitigating the burden of such diseases. Objectives To examine the association between seasonal influenza vaccination and antimicrobial use (AMU) in Japan at the community level and to examine the impact of influenza vaccination on the frequency of unnecessary antimicrobial prescription for upper respiratory infection. Methods For patients who visited any healthcare facility in one of the 23 wards of Tokyo, Japan, due to upper respiratory infection and who were aged 65 years or older, we extracted data from the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study database, which includes all claims data and vaccination records from the 2015–16 to 2020–21 seasons. We used the average treatment effect (ATE) with 1:1 propensity score matching to examine the association of vaccination status with frequency of antibiotic prescription, frequency of healthcare facility consultation, risk of admission and risk of death in the follow-up period of the same season (from 1 January to 31 March). Results In total, 244 642 people were enrolled. Matched data included 101 734 people in each of the unvaccinated and vaccinated groups. The ATE of vaccination was −0.004 (95% CI −0.006 to −0.002) for the frequency of antibiotic prescription, −0.005 (−0.007 to −0.004) for the frequency of healthcare facility consultation, −0.001 (−0.002 to −0.001) for the risk of admission and 0.00 (0.00 to 0.00) for the risk of death. Conclusions Our results suggest that seasonal influenza vaccination is associated with lower frequencies of unnecessary antibiotic prescription and of healthcare facility consultation.

show abstract

Effectiveness of influenza vaccination in reducing influenza-like illness and related antibiotic prescriptions in adults from a primary care-based case-control study

Cited by 5 publications

References 19 publications

Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection

Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection

Human monoclonal antibodies protect against viral-mediated pneumococcal superinfection

Association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015–16 to 2020–21 seasons: from the VENUS study

Contact Info

Product

Resources

About